The Age-Specific Impact of Cellular Immunity on Long-Term Outcome after Acute Coronary Syndrome

Abstract

Background Personalized risk stratification after acute coronary syndrome (ACS) remains a challenging field in the aging society. Easily applicable strategies for risk prediction of adverse events from an age-specific perspective are needed. Considering the association of cellular immunity with coronary vessel disease, these cell lines mirror a reasonable value for risk assessment. Therefore, we aimed to elucidate the prognostic value of cellular immunity on long-term outcome after ACS from an age-specific perspective.

Methods Patients presenting with ACS at the Vienna General Hospital admitted between December 1996 and January 2010 were enrolled within a clinical registry including standardized assessment of peripheral blood samples and immune phenotyping. Cox-regression hazards analysis was performed to elucidate the impact of cellular immunity on survival.

Results A total of 832 patients were included within the final analysis and stratified according to age into individuals <65 years (n = 416) and ≥65 years (n = 416). After a median follow-up time of 8.6 years, a total of 516 (62.0%) individuals died. We found that the fraction of lymphocytes (adjusted hazard ratio [HR] of 0.61 [95% confidence interval, CI: 0.45–0.82]; p = 0.001), the fraction of neutrophil granulocytes (adjusted HR of 5.01 [95% CI: 1.62–15.46]; p = 0.005), and the neutrophil-to-lymphocyte ratio (NLR; adjusted HR of 1.47 [95% CI: 1.16–1.87]; p = 0.002) showed a strong and independent association with mortality in individuals ≥65 years. Notably, there was no effect on outcome observed for any of the tested cell lines in patients <65 years.

Conclusion The present investigation highlighted a strong and independent age-specific effect of both the fraction of neutrophil granulocytes and lymphocytes as well as the NLR on outcome. Considering an age-dependent risk stratification, these routinely available values can be easily used to identify patients at risk for fatal events and contribute to proper secondary prevention after ACS.

Keywords

immunity - coronary syndrome - inflammation

Publikationsverlauf

Eingereicht: 31. August 2020

Angenommen: 15. Dezember 2020

Accepted Manuscript online:
18. Dezember 2020

Artikel online veröffentlicht:
10. Februar 2021

• References

• 1 Timmis A, Townsend N, Gale C. et al; ESC Scientific Document Group. European Society of Cardiology: cardiovascular disease statistics 2017. Eur Heart J 2018; 39 (07) 508-579
• 2 United Nations, Department of Economic and Social Affairs, Population Division. World population ageing, 2019 highlights. 2020 . Accessed January 6, 2021 at: https://www.un.org/en/development/desa/population/publications/pdf/ageing/WorldPopulationAgeing2019-Highlights.pdf
• 3 Libby P, Ridker PM, Hansson GK. Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 2009; 54 (23) 2129-2138
• 4 Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res 2012; 110 (01) 159-173
• 5 Barron HV, Cannon CP, Murphy SA, Braunwald E, Gibson CM. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction : a thrombolysis in myocardial infarction 10 substudy. Circulation 2000; 102 (19) 2329-2334
• 6 Sabatine MS, Morrow DA, Cannon CP. et al. Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy- Thrombolysis in Myocardial Infarction 18 trial)substudy. J Am Coll Cardiol 2002; 40 (10) 1761-1768
• 7 Cannon CP, McCabe CH, Wilcox RG, Bentley JH, Braunwald E. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. OPUS-TIMI 16 Investigators. Am J Cardiol 2001; 87 (05) 636-639 , A10
• 8 Sulzgruber P, El-Hamid F, Koller L. et al. Long-term outcome and risk prediction in patients suffering acute myocardial infarction complicated by post-infarction cardiac rupture. Int J Cardiol 2017; 227: 399-403
• 9 Steg PG, James SK, Atar D. et al; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20) 2569-2619
• 10 Roffi M, Patrono C, Collet J-P. et al; ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent st-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
• 11 Williams B, Mancia G, Spiering W. et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33) 3021-3104
• 12 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018; 71 (19) e127-e248
• 13 Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30 (07) 1282-1292
• 14 Cristell N, Cianflone D, Durante A. et al; FAMI Study Investigators. High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study. J Am Coll Cardiol 2011; 58 (25) 2654-2661
• 15 Thomas MR, James SK, Becker RC. et al. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. Eur Heart J Acute Cardiovasc Care 2019; DOI: 10.1177/2048872619878075.
• 16 Kaya MG, Akpek M, Lam YY. et al. Prognostic value of neutrophil/lymphocyte ratio in patients with ST-elevated myocardial infarction undergoing primary coronary intervention: a prospective, multicenter study. Int J Cardiol 2013; 168 (02) 1154-1159
• 17 Wang X, Zhang G, Jiang X, Zhu H, Lu Z, Xu L. Neutrophil to lymphocyte ratio in relation to risk of all-cause mortality and cardiovascular events among patients undergoing angiography or cardiac revascularization: a meta-analysis of observational studies. Atherosclerosis 2014; 234 (01) 206-213
• 18 Wada H, Dohi T, Miyauchi K. et al. Pre-procedural neutrophil-to-lymphocyte ratio and long-term cardiac outcomes after percutaneous coronary intervention for stable coronary artery disease. Atherosclerosis 2017; 265: 35-40
• 19 Li W, Liu Q, Tang Y. Platelet to lymphocyte ratio in the prediction of adverse outcomes after acute coronary syndrome: a meta-analysis. Sci Rep 2017; 7 (01) 40426
• 20 Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005; 111 (11) 1448-1454
• 21 Liuzzo G, Goronzy JJ, Yang H. et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101 (25) 2883-2888
• 22 Liuzzo G, Kopecky SL, Frye RL. et al. Perturbation of the T-cell repertoire in patients with unstable angina. Circulation 1999; 100 (21) 2135-2139
• 23 Hammer A, Sulzgruber P, Koller L. et al. The prognostic impact of circulating regulatory T lymphocytes on mortality in patients with ischemic heart failure with reduced ejection fraction. Mediators Inflamm 2020; 2020: 6079713
• 24 Sulzgruber P, Koller L, Winter M-P. et al. The impact of CD4⁺CD28^null T-lymphocytes on atrial fibrillation and mortality in patients with chronic heart failure. Thromb Haemost 2017; 117 (02) 349-356
• 25 Kazem N, Sulzgruber P, Thaler B. et al. CD8+CD28null T lymphocytes are associated with the development of atrial fibrillation after elective cardiac surgery. Thromb Haemost 2020; 120 (08) 1182-1187
• 26 Tran HV, Erskine NA, Nguyen HL. et al. Increase in white blood cell count is associated with the development of atrial fibrillation after an acute coronary syndrome. Int J Cardiol 2019; 274: 138-143
• 27 Zaman MJ, Stirling S, Shepstone L. et al. The association between older age and receipt of care and outcomes in patients with acute coronary syndromes: a cohort study of the Myocardial Ischaemia National Audit Project (MINAP). Eur Heart J 2014; 35 (23) 1551-1558
• 28 Avezum A, Makdisse M, Spencer F. et al; GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2005; 149 (01) 67-73
• 29 Ridker PM, Everett BM, Thuren T. et al; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377 (12) 1119-1131
• 30 Catapano AL, Pirillo A, Norata GD. Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Br J Pharmacol 2017; 174 (22) 3973-3985
• 31 Baigent C, Koskinas KC, Casula M, Badimon L, Chapman MJ, Backer GGD. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2020; 41 (01) 111-188